Rare coagulation disorders

Research output: Contribution to journalArticle

Abstract

The type of hemorrhagic manifestations that occur in patients with recessively transmitted coagulation disorders and their optimal treatment are not well established as for hemophilia A and B and von Willebrand disease, due to the rarity of these disorders. In a Muslim country like Iran when consanguineous marriages are frequent these disorders are less rare. We chose to evaluate the pattern of bleeding symptoms in 237 Iranian patients with the inherited deficiencies of fibrinogen, factor II, combined factor V and factor VIII, factor V, factor VII and factor X. Considering 'severe' life-endangering hemorrhages such as those in the CNS, gastrointestinal tract and from the umbilical cord and those potentially handicapping such as hematomas and hemarthroses, and 'mild' epistaxis, menorrhagia, hematuria, oral and postsurgical bleeding, it would appear the most severe diseases are factor X and factor II deficiencies. For the remaining defects only a minority of patients, even those with unmeasurable plasma levels, had life endangering hemorrhages or muscoloskeletal disabilities as a consequence of hemarthroses and hematomas. The relatively mild severity of clinical manifestations in recessive coagulation disorders commands safety as the primary criterion in the choice of replacement material for treatment. Hence, virally inactivated plasma and factor concentrates should be the products of choice.

Original languageEnglish
Pages (from-to)1207-1214
Number of pages8
JournalThrombosis and Haemostasis
Volume82
Issue number4
Publication statusPublished - 1999

Fingerprint

Hypoprothrombinemias
Hemarthrosis
Hemorrhage
Factor X
Factor V
Hematoma
Hemophilia B
Menorrhagia
von Willebrand Diseases
Islam
Epistaxis
Factor VII
Umbilical Cord
Factor VIII
Hemophilia A
Hematuria
Iran
Marriage
Gastrointestinal Tract
Safety

Keywords

  • Afibrinogenemia
  • Factor II
  • Factor V
  • Factor VII
  • Factor X
  • Inherited coagulation disorders

ASJC Scopus subject areas

  • Hematology

Cite this

Rare coagulation disorders. / Peyvandi, Flora; Mannucci, P. M.

In: Thrombosis and Haemostasis, Vol. 82, No. 4, 1999, p. 1207-1214.

Research output: Contribution to journalArticle

@article{a892ceaa54fe44e89444a890d4dded5b,
title = "Rare coagulation disorders",
abstract = "The type of hemorrhagic manifestations that occur in patients with recessively transmitted coagulation disorders and their optimal treatment are not well established as for hemophilia A and B and von Willebrand disease, due to the rarity of these disorders. In a Muslim country like Iran when consanguineous marriages are frequent these disorders are less rare. We chose to evaluate the pattern of bleeding symptoms in 237 Iranian patients with the inherited deficiencies of fibrinogen, factor II, combined factor V and factor VIII, factor V, factor VII and factor X. Considering 'severe' life-endangering hemorrhages such as those in the CNS, gastrointestinal tract and from the umbilical cord and those potentially handicapping such as hematomas and hemarthroses, and 'mild' epistaxis, menorrhagia, hematuria, oral and postsurgical bleeding, it would appear the most severe diseases are factor X and factor II deficiencies. For the remaining defects only a minority of patients, even those with unmeasurable plasma levels, had life endangering hemorrhages or muscoloskeletal disabilities as a consequence of hemarthroses and hematomas. The relatively mild severity of clinical manifestations in recessive coagulation disorders commands safety as the primary criterion in the choice of replacement material for treatment. Hence, virally inactivated plasma and factor concentrates should be the products of choice.",
keywords = "Afibrinogenemia, Factor II, Factor V, Factor VII, Factor X, Inherited coagulation disorders",
author = "Flora Peyvandi and Mannucci, {P. M.}",
year = "1999",
language = "English",
volume = "82",
pages = "1207--1214",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Rare coagulation disorders

AU - Peyvandi, Flora

AU - Mannucci, P. M.

PY - 1999

Y1 - 1999

N2 - The type of hemorrhagic manifestations that occur in patients with recessively transmitted coagulation disorders and their optimal treatment are not well established as for hemophilia A and B and von Willebrand disease, due to the rarity of these disorders. In a Muslim country like Iran when consanguineous marriages are frequent these disorders are less rare. We chose to evaluate the pattern of bleeding symptoms in 237 Iranian patients with the inherited deficiencies of fibrinogen, factor II, combined factor V and factor VIII, factor V, factor VII and factor X. Considering 'severe' life-endangering hemorrhages such as those in the CNS, gastrointestinal tract and from the umbilical cord and those potentially handicapping such as hematomas and hemarthroses, and 'mild' epistaxis, menorrhagia, hematuria, oral and postsurgical bleeding, it would appear the most severe diseases are factor X and factor II deficiencies. For the remaining defects only a minority of patients, even those with unmeasurable plasma levels, had life endangering hemorrhages or muscoloskeletal disabilities as a consequence of hemarthroses and hematomas. The relatively mild severity of clinical manifestations in recessive coagulation disorders commands safety as the primary criterion in the choice of replacement material for treatment. Hence, virally inactivated plasma and factor concentrates should be the products of choice.

AB - The type of hemorrhagic manifestations that occur in patients with recessively transmitted coagulation disorders and their optimal treatment are not well established as for hemophilia A and B and von Willebrand disease, due to the rarity of these disorders. In a Muslim country like Iran when consanguineous marriages are frequent these disorders are less rare. We chose to evaluate the pattern of bleeding symptoms in 237 Iranian patients with the inherited deficiencies of fibrinogen, factor II, combined factor V and factor VIII, factor V, factor VII and factor X. Considering 'severe' life-endangering hemorrhages such as those in the CNS, gastrointestinal tract and from the umbilical cord and those potentially handicapping such as hematomas and hemarthroses, and 'mild' epistaxis, menorrhagia, hematuria, oral and postsurgical bleeding, it would appear the most severe diseases are factor X and factor II deficiencies. For the remaining defects only a minority of patients, even those with unmeasurable plasma levels, had life endangering hemorrhages or muscoloskeletal disabilities as a consequence of hemarthroses and hematomas. The relatively mild severity of clinical manifestations in recessive coagulation disorders commands safety as the primary criterion in the choice of replacement material for treatment. Hence, virally inactivated plasma and factor concentrates should be the products of choice.

KW - Afibrinogenemia

KW - Factor II

KW - Factor V

KW - Factor VII

KW - Factor X

KW - Inherited coagulation disorders

UR - http://www.scopus.com/inward/record.url?scp=0032845564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845564&partnerID=8YFLogxK

M3 - Article

C2 - 10544899

AN - SCOPUS:0032845564

VL - 82

SP - 1207

EP - 1214

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -